Natco Pharma inks pact with Eli Lilly for Covid drug Baricitinib
Published: May 17, 2021
By TIOLCORPLAWS News Service
HYDERABAD, MAY 17, 2021: NATCO Pharma on Monday said it has signed a voluntary licensing agreement with pharmaceutical major Eli Lilly and Company to manufacture and commercialise the anti-Covid drug Baricitinib in India.
Eli Lilly has issued a royalty-free, non-exclusive voluntary license to Natco Pharma to further accelerate and expand the availability of the drug. It has signed six similar agreements with Cipla, Lupin, Sun Pharmaceutical Industries, Dr Reddy's, MSN Laboratories and Torrent Pharmaceuticals.
Natco has received emergency use authorisation from the Central Drugs Standard Control Organisation (CDSCO), for using Baricitinib in combination with Remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.